134 results
8-K
EX-99.1
GALT
Galectin Therapeutics Inc.
13 Jan 25
Regulation FD Disclosure
8:00am
≥ 14 cm Collaterals by imaging Stiffness ≥ 20 kPa Development of new varices (composite strategy) in ITT population- Number of subjects with varices … 2014 Galectin Therapeutics | NASDAQ: GALT ITT: All randomized subjects Primary end point composite strategy i.e. new varices and or intercurrent
8-K
EX-10.1
GALT
Galectin Therapeutics Inc.
1 Aug 24
Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer
7:50am
to, serving as the subject matter expert and leader of developmental efforts and strategy for a portfolio of products in various stages of development … efforts and strategy for a portfolio of products in various stages of development; (ii) customarily and regularly solicits for the Company customers
8-K
EX-99.1
soogz jt86lh
1 Dec 22
Regulation FD Disclosure
11:00am
8-K
EX-99.1
929qdc6q8e5gzg 1jbv
26 Jul 22
Galectin Therapeutics Announces $60 Million Credit Line
7:57am
8-K
EX-99.1
usjhj9j7s3pxoydb
16 May 22
Results of Operations and Financial Condition
7:55am